This 10mg blend combines BPC-157 5mg and TB-500 5mg in a single vial. Both peptides are synthesized and lyophilized in the USA, with batch purity verified by HPLC-MS above 99%.
Each vial of BPC-157 & TB-500 Blend (10mg) contains a pre-weighed ratio of BPC-157 5mg, TB-500 5mg in a single lyophilized cake, simplifying multi-peptide research protocols.
Researchers studying BPC-157 & TB-500 Blend (10mg) use controlled injury or stress models to observe changes in recovery-related endpoints.
BPC-157 & TB-500 Blend (10mg) is often included in comparative panels alongside other short-chain repair peptides to map functional differences.
Laboratory work on BPC-157 & TB-500 Blend (10mg) emphasizes reproducible dosing and purity verification before experimental application.
Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.
Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.
Research & Literature
The following peer-reviewed studies and reference documents are commonly consulted by researchers working with BPC-157 & TB-500 Blend (10mg). Summaries are provided for orientation only and reflect the cited sources.
The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration[1] — This study investigated the effects of the pentadecapeptide BPC 157 on tendon healing, focusing on tendon outgrowth, cell survival, and cell migration. The authors examined the cellular mechanisms through which BPC 157 may promote tendon repair. The findings suggested that BPC 157 supports the regenerative processes underlying tendon recovery. (Journal of Applied Physiology 2011)
The pharmacological properties of the novel peptide BPC 157 (PL-10)[2] — This review described the pharmacological profile of the pentadecapeptide BPC 157, also referred to as PL-10. The author summarized its reported effects on gastrointestinal protection, inflammation, and tissue healing. The review provided an early comprehensive account of BPC 157's biological activities. (Inflammopharmacology 1999)
Thymosin beta 4 Promotes Dermal Healing[3] — This review chapter examined the role of thymosin beta 4 in dermal wound healing, with particular attention to its actin-binding motif that is also present in the TB-500 component of this blend. The authors discussed how thymosin beta 4 influences cell migration, survival, and inflammatory responses during tissue repair. These mechanisms help explain the proposed regenerative properties of TB-500 in skin and other soft tissues. (Vitamins and Hormones 2016)
Thymosin beta 4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway[4] — This study investigated how thymosin beta 4 regulates oligodendrocyte differentiation through upregulation of microRNA-146a. The findings indicated that thymosin beta 4 can suppress the Toll-like receptor proinflammatory pathway while promoting the maturation of myelin-forming cells. This suggests broader anti-inflammatory and neuroprotective activities for thymosin beta 4 that extend beyond its well-known wound-healing effects. (Journal of Biological Chemistry 2014)
References
Chang CH, et al.. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." Journal of Applied Physiology. 2011. pubmed.ncbi.nlm.nih.gov/21030672/
Sikiric P. "The pharmacological properties of the novel peptide BPC 157 (PL-10)." Inflammopharmacology. 1999. pubmed.ncbi.nlm.nih.gov/17657443/
Santra M, et al.. "Thymosin beta 4 up-regulation of microRNA-146a promotes oligodendrocyte differentiation and suppression of the Toll-like proinflammatory pathway." Journal of Biological Chemistry. 2014. doi.org/10.1074/jbc.M113.529966
All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.
Which research areas commonly use BPC-157 & TB-500 Blend (10mg)?
BPC-157 & TB-500 Blend (10mg) is most often referenced in studies related to tissue repair, cytoprotection, and extracellular matrix remodeling. Typical laboratory protocols combine dose-response assays with purity verification before experimental application.
What is the purity of BPC-157 & TB-500 Blend (10mg)?
All batches are purified by reversed-phase HPLC and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request.
How is BPC-157 & TB-500 Blend (10mg) packaged?
Each vial contains lyophilized peptide at the labeled quantity. Wholesale orders are packed in boxes of ten vials at a single per-vial price.
How should BPC-157 & TB-500 Blend (10mg) be stored?
Store lyophilized vials at -20°C, protected from light and moisture. Reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles.
Is BPC-157 & TB-500 Blend (10mg) for human or veterinary use?
No. All products are supplied for in-vitro laboratory research use only and are not for human or veterinary use.
Batch Certificates of Analysis
Every production batch of this product is analyzed by HPLC (purity) and mass spectrometry (identity). Certificates accompany each order and are available on request for any batch.
HPLC-UV purity report with chromatogram
MS identity report with molecular weight confirmation
